Capital strength varied sharply across providers despite broadly stable industry-wide financial buffers.
Financial capital levels across South Korea’s life insurance sector remained broadly stable quarter-on-quarter at the end of June 2026, though individual insurers showed significant differences in performance, according to CreditSights.
Data for the second quarter shows the industry’s post-transitional Insurance Capital Standard (K-ICS) ratio dropped 0.7 percentage points to 206.8%.
Meanwhile, the underlying ratio, which excludes relief measures, rose 2.5 percentage points to 193.0%.
Across the sector, post-transition solvency figures ranged widely, from 138.3% at Hana Life to 396.4% at NongHyup Life.
Results varied noticeably amongst major firms. Hanwha Life reported an improvement in its capital ratio to 168.0%, up 5.9 percentage points from the previous quarter.
The company credited higher interest rates, foreign exchange effects, and new contractual service margin gains, with management aiming to keep the ratio above 165% by the end of the year.
By contrast, Kyobo Life recorded a 5.0 percentage point decline in its underlying ratio to 155.4%.
Tighter actuarial assumptions and capital allocated to its SBI Savings-related acquisition weighed on the firm’s position.
Solvency directions diverged sharply across other providers. NongHyup Life recorded a 21.8 percentage point surge to reach 396.4%, whereas KB Life fell 28.8 percentage points to 223.4%.
Several providers continue to rely heavily on temporary regulatory relief, with pre-transition ratios at Fubon Hyundai Life and KDB Life remaining substantially lower than their post-transition figures.
Higher interest rates are expected to support overall insurer balance sheets moving forward, though stricter accounting and actuarial standards present a short-term risk to profitability and capital reserves.
Financial analysts maintain a Market Perform rating on both Hanwha Life and Kyobo Life. No official coverage recommendation is held on Tong Yang Life, which is progressing with a merger alongside ABL Life, though analysts consider its bonds to be trading at a fair valuation.